Global Wholehealth Partners Corp. (GWHP)

[billionsmatter]

FORM 8-K Filed have a read

GLOBAL WHOLEHEALTH PARTNERS CORP
FORM 8-K
(Current report filing)
Filed 09/15/20 for the Period Ending 09/14/20

Address 2227 AVENIDA OLIVA
SAN CLEMENTE, CA, 92673
Telephone [phone]
CIK 0001598308
Symbol GWHP
SIC Code 2835 - In Vitro and In Vivo Diagnostic Substances
Industry Healthcare Facilities & Services
Sector Healthcare
Fiscal Year 06/30
http://www.edgar-online.com
© Copyright 2020, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2020
GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Exact name of registrant as specified in its charter)
Nevada 000-56035 46-2316220
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)
2227 Avenida Oliva
San Clemente, CA 92673
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code [phone]
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.?
Section 8 - Other Events
Item 8.01 Other Events.
On September 14, 2020, Global Wholehealth Partners Corporation (the “Company”) received an Acknowledgment Letter (the “Letter”) from
the U.S. Food and Drug Administration (the “FDA”) that the Center for Devices and Radiological Health of the FDA has received the
Company’s Global Rapid Antigen Test test application submitted by Charles Strongo, the Company’s Chief Executive Officer. The
Company’s submission has been assigned the unique document control number PEUA201789.
A copy of the Letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Section 9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Document Location
99.1 FDA Letter received September 14, 2020. Filed Herewith
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
Date: September 14, 2020 By: /s/ Charles Strongo
Charles Strongo
Chief Executive Officer


https://www.otcmarkets.com/filing/conv_pdf?id=14390618&guid=45o6UF7exZFK93h